EMA Lays Out Plans For Routine Use Of Real-World Evidence
EU Draft Artificial Intelligence Guideline Slated For November 2022
Executive Summary
A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year by various European Medicines Agency scientific committees.
You may also be interested in...
EMA’s Pediatrics Group To Focus On ‘Stepwise’ PIPs & Using RWE In 2024
The European Medicines Agency has drawn up an action plan for its pediatrics committee that will see existing initiatives, such as the introduction of a ‘stepwise’ approach to pediatric investigation plans, further developed this year.
Review Identifies Opportunities To Help EMA Realize Full Potential Of RWE
An EU review shows the great potential of regulator-led real-world evidence studies to address a range of research questions for regulatory decision making. It also provides learnings and recommendations for future improvements to the RWE framework being drawn up by the European Medicines Agency alongside the European medicines regulatory network.
EMA To See If Reviewing Patient-Level Data Can Speed Up Drug Evaluations
A two-year pilot will explore the many potential benefits that the analysis of raw data can bring to the EU drug evaluation process. These range from faster patient access to medicines, companies facing fewer questions, and better definition of the target treatment population.